Selected References
- Wang Y, Bartelsen N, Arnold P, Mueller-Schmucker S, Weingärtner C, Beutel J, Eichler J, Temchura V, Damm D, Überla K. (2025). Development and characterization of a human papillomavirus-based nanoparticle carrier for heterologous vaccine antigens. Sci Rep. 15(1): 32927.
- Di Vincenzo R, Beutel J, Arnold P, Wang Y, Damm D, Tannig P, Lux A, Temchura V, Eichler J, Überla K. (2024). Oriented display of HIV-1 Env trimers by a novel coupling strategy enhances B cell activation and phagocytosis. Front Immunol. 15: 1344346.
- Stahl-Hennig C, Peter AS, Cordsmeier A, Stolte-Leeb N, Vestweber R, Socher E, Merida SA, Sauermann U, Bleyer M, Fraedrich K, Grunwald T, Winkler TH, Ensser A, Jäck H-M, Überla K. (2024). Genetic barrier to resistance: a critical parameter for efficacy of neutralizing monoclonal antibodies against SARS-CoV-2 in a nonhuman primate model. J Virol. 98(7): e0062824.
- Wagner JT, Müller-Schmucker SM, Wang W, Arnold P, Uhlig N, Issmail L, Eberlein V, Damm D, Roshanbinfar K, Ensser A, Oltmanns F, Peter AS, Temchura V, Schrödel S, Engel FB, Thirion C, Grunwald T, Wuhrer M, Grimm D, Überla K. (2024) Influence of AAV vector tropism on long-term expression and Fc-γ receptor binding of an antibody targeting SARS-CoV-2. Commun Biol. 7(1): 865.
- Richel E, Cordsmeier A, Bauer L, Fraedrich K, Vestweber R, Roshani B, Stolte-Leeb N, Ensser A, Stahl-Hennig C, Überla K. (2024) Mechanisms of sterilizing immunity provided by an HIV-1 neutralizing antibody against mucosal infection. PLoS Pathog. 20(12): e1012777.
- Stab V, Stahl-Hennig C, Ensser A, Richel E, Fraedrich K , Sauermann U, Tippler B, Klein F, Burton DR, Tenbusch M, Überla K (2023). HIV-1 neutralizing antibodies provide sterilizing immunity by blocking infection of the first cells. Cell Rep Med 17: 101201. doi: 10.1016/j.xcrm.2023.101201
- Klessing S, Temchura V, Tannig P, Peter AS, Christensen D, Lang R, Überla K. (2020). CD4+ T Cells Induced by Tuberculosis Subunit Vaccine H1 Can Improve the HIV-1 Env Humoral Response by Intrastructural Help. Vaccines, 8: 604. doi: 10.3390/vaccines8040604.
- Damm D, Suleiman E, Theobald H, Wagner JT, Batzoni M, Ahlfeld Née Kohlhauser B, Walkenfort B, Albrecht JC, Ingale J, Yang L, Hasenberg M, Wyatt RT, Vorauer-Uhl K, Überla K, Temchura V. (2022). Design and Functional Characterization of HIV-1 Envelope Protein-Coupled T Helper Liposomes. Pharmaceutics, 14(7): 1385.
- Peter AS, Roth E, Schulz SR, Fraedrich K, Steinmetz T, Damm D, Hauke M, Richel E, Mueller-Schmucker S, Habenicht K, Eberlein V, Issmail L, Uhlig N, Dolles S, Grüner E, Peterhoff D, Ciesek S, Hoffmann M, Pöhlmann S, McKay PF, Shattock RJ, Wölfel R, Socher E, Wagner R, Eichler J, Sticht H, Schuh W, Neipel F, Ensser A, Mielenz D, Tenbusch M, Winkler TH, Grunwald T, Überla K, Jäck HM. (2022). A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model. Eur J Immunol, 52(5): 770-783.
- Peterhoff D, Einhauser S, Beileke S, Niller HH, Günther F, Schachtner M, Asbach B, Steininger P, Tenbusch M, Peter AS, Gessner A, Burkhardt R, Heid IM, Wagner R, Überla K. (2022). Comparative Immunogenicity of COVID-19 Vaccines in a Population-Based Cohort Study with SARS-CoV-2-Infected and Uninfected Participants. Vaccines, 10(2): 324.
- Wratil PR, Stern M, Priller A, Willmann A, Almanzar G, Vogel E, Feuerherd M, Cheng CC, Yazici S, Christa C, Jeske S, Lupoli G, Vogt T, Albanese M, Mejías-Pérez E, Bauernfried S, Graf N, Mijocevic H, Vu M, Tinnefeld K, Wettengel J, Hoffmann D, Muenchhoff M, Daechert C, Mairhofer H, Krebs S, Fingerle V, Graf A, Steininger P, Blum H, Hornung V, Liebl B, Überla K, Prelog M, Knolle P, Keppler OT, Protzer U. (2022). Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern. Nat Med, 28(3): 496-503.
- Tenbusch M, Schumacher S, Vogel E, Priller A, Held J, Steininger P, Beileke S, Irrgang P, Brockhoff R, Salmanton-García J, Tinnefeld K, Mijocevic H, Schober K, Bogdan C, Yazici S, Knolle P, Cornely OA, Überla K, Protzer U. (2021). Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2. Lancet Infect Dis, 21(9): 1212-1213.
- Lapuente D, Fuchs J, Willar J, Vieira Antão A, Eberlein V, Uhlig N, Issmail L, Schmidt A, Oltmanns F, Peter AS, Mueller-Schmucker S, Irrgang P, Fraedrich K, Cara A, Hoffmann M, Pöhlmann S, Ensser A, Pertl C, Willert T, Thirion C, Grunwald T, Überla K, Tenbusch M. (2021). Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization. Nat Commun, 12(1): 6871.
- Wagner R, Peterhoff D, Beileke S, Günther F, Berr M, Einhauser S, Schütz A, Niller HH, Steininger P, Knöll A, Tenbusch M, Maier C, Korn K, Stark KJ, Gessner A, Burkhardt R, Kabesch M, Schedl H, Küchenhoff H, Pfahlberg AB, Heid IM, Gefeller O, Überla K. (2021). Estimates and Determinants of SARS-Cov-2 Seroprevalence and Infection Fatality Ratio Using Latent Class Analysis: The Population-Based Tirschenreuth Study in the Hardest-Hit German County in Spring 2020. Viruses, 13(6): 1118.
